Harnessing Immune Response in Acute Myeloid Leukemia

Despite the results achieved with the evolution of conventional chemotherapy and the inclusion of targeted therapies in the treatment of acute myeloid leukemia (AML), survival is still not satisfying, in particular in the setting of relapsed/refractory (R/R) disease or elderly/unfit patients. Among...

Descripción completa

Detalles Bibliográficos
Autores principales: Riva, Carola, Vernarecci, Chiara, Minetto, Paola, Goda, Rayan, Greppi, Marco, Pesce, Silvia, Chies, Maria, Zecchetti, Giada, Ferro, Beatrice, Maio, Elena, Cea, Michele, Lemoli, Roberto Massimo, Marcenaro, Emanuela, Guolo, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532363/
https://www.ncbi.nlm.nih.gov/pubmed/37762763
http://dx.doi.org/10.3390/jcm12185824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532363/
https://www.ncbi.nlm.nih.gov/pubmed/37762763
http://dx.doi.org/10.3390/jcm12185824

Ejemplares similares